High expression of FASN also significantly correlated with HER2+ status and brain metastasis, suggesting FASN could serve as a potential biomarker for distinguishing HER2-enriched breast cancer and predicting metastasis at later stage of malignancy. Here, ERBB2 is linked to breast carcinoma.